NCT01403662View on ClinicalTrials.gov

Evaluating the Efficacy of Adjunctive Minocycline for the Treatment of Bipolar Depression

PHASE3CompletedINTERVENTIONAL
Enrollment

29

Participants

Timeline

Start Date

July 31, 2011

Primary Completion Date

February 28, 2014

Study Completion Date

December 31, 2014

Conditions
Bipolar DisorderBipolar DepressionBipolar I DepressionBipolar II Depression
Interventions
DRUG

Minocycline

Minocycline (100 mg bid) will be administered as an adjunctive agent to conventional Health Canada-approved, or first-line CANMAT bipolar guideline-recommended, agents for bipolar disorder.

Trial Locations (1)

M5T 2S8

University Health Network, Toronto

All Listed Sponsors
lead

University Health Network, Toronto

OTHER

NCT01403662 - Evaluating the Efficacy of Adjunctive Minocycline for the Treatment of Bipolar Depression | Biotech Hunter | Biotech Hunter